Alnylam reports positive topline results from phase 2 study of investigational cemdisiran for the treatment of iga nephropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) announced today topline results from the phase 2 study of cemdisiran, an investigational rnai therapeutic targeting the c5 component of the complement pathway that is in development in collaboration with regeneron pharmaceuticals for the treatment of immunoglobulin a nephropathy (igan). at week 32, treatment with cemdisiran resulted in a 37 percent mean reduction from baseline in the 24-hour urine protein to creatin
ALNY Ratings Summary
ALNY Quant Ranking